Relmada Therapeutics says CMO-Urology Raj S. Pruthi departs
RLMD•CMO-Urology departure
- Relmada Therapeutics’ Chief Medical Officer – Urology, Raj S. Pruthi, left the company on Sept. 3, 2026.
Related News
Veru plans Phase 2 trial of oral sabizabulin in daraxonrasib-resistant metastatic pancreatic cancer
VERU•
Octave Specialty Group names Philip Stefano head of investor relations
OSG•
Vivmark Residential <VMRK.N>: Mizuho raises to outperform from neutral; raises target price to $73 from $70
VMRK•
Interparfums Inc., linked to directors Jean Madar and Philippe Benacin, purchases EUR 137,650 in Inter Parfums SA shares
IPAR•
MarketAxess announces R$ 0.05 per unit dividend, payable Sept. 9
MKTX•